In conclusion, we provided evidence that the treatment with RDV can protect mice against LPS-induced AKI by specially inhibiting NLRP3 inflammasome activation in macrophages, thereby reducing inflammation-induced renal damage and improving the recovery of renal function. The gene discussed is NLRP3; the disease is acute kidney injury.